Kiniksa Pharmaceuticals International, plc (KNSA) /
The cash flow of Kiniksa Pharmaceuticals International, plc over the past 9 years
Chart Kiniksa Pharmaceuticals International, plc: operating cash flow, capital expenditures, free cash flow, fiscal 2017–2025 Open the chart →In fiscal 2025, the latest fiscal year on file, Kiniksa Pharmaceuticals International, plc's operating cash flow was $137.99M and its capital expenditures $1.57M, leaving free cash flow of $136.42M. Free cash flow was above zero in 4 of the 9 years shown. It ranged from -$161.57M in fiscal 2019 to $136.42M in fiscal 2025. Capital expenditures were highest in fiscal 2018, at $5.29M.
Year by year
| Fiscal year | Operating cash flow | Capital expenditures | Free cash flow* |
|---|---|---|---|
| 2025ended Dec 31, 2025 | $137.99M | $1.57M | $136.42M |
| 2024ended Dec 31, 2024 | $25.69M | $277K | $25.41M |
| 2023ended Dec 31, 2023 | $13.3M | $130K | $13.17M |
| 2022ended Dec 31, 2022 | $5.81M | $105K | $5.7M |
| 2021ended Dec 31, 2021 | -$126.3M | $415K | -$126.71M |
| 2020ended Dec 31, 2020 | -$136.53M | $283K | -$136.81M |
| 2019ended Dec 31, 2019 | -$158.37M | $3.2M | -$161.57M |
| 2018ended Dec 31, 2018 | -$81.01M | $5.29M | -$86.3M |
| 2017ended Dec 31, 2017 | -$50.22M | $69K | -$50.29M |
Fiscal years as Kiniksa Pharmaceuticals International, plc reports them. * Calculated by us from the company's filed figures; — no figure on file. From SEC filings, updated nightly. How each line is read.
More on Kiniksa Pharmaceuticals International, plc
- The revenue of Kiniksa Pharmaceuticals International, plc
- The profitability of Kiniksa Pharmaceuticals International, plc
- The debt of Kiniksa Pharmaceuticals International, plc
- All of Kiniksa Pharmaceuticals International, plc's financials, charted
Companies of a similar size
- CAVACAVA Group, Inc.
- WFRDWeatherford International plc
- MSMMSC INDUSTRIAL DIRECT CO., INC.
- KVYOKlaviyo, Inc.
- DOCSDoximity, Inc.
Not investment advice. This page shows what Kiniksa Pharmaceuticals International, plc filed with the SEC. Nothing here is a recommendation about any security. Check important figures against the company's own filings.